نتایج جستجو برای: metalated flavopiridol

تعداد نتایج: 668  

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2002
Ivana Gojo Bin Zhang Robert G Fenton

Multiple myeloma (MM) is a B-cell malignancy characterized by the accumulation of malignant plasma cells with slow proliferative rate but enhanced survival. MM cells express multiple Bcl-2 family members, including Bcl-2, Bcl-XL, and Mcl-1, which are thought to play a key role in the survival and drug resistance of myeloma. The cyclin-dependent kinase inhibitor flavopiridol has antitumor activi...

Journal: :Haematologica 2012
Judith E Karp Elizabeth Garrett-Mayer Elihu H Estey Michelle A Rudek B Douglas Smith Jacqueline M Greer D Michelle Drye Karen Mackey Kathleen Shannon Dorcy Steven D Gore Mark J Levis Michael A McDevitt Hetty E Carraway Keith W Pratz Douglas E Gladstone Margaret M Showel Megan Othus L Austin Doyle John J Wright John M Pagel

BACKGROUND Flavopiridol is a protein-bound, cytotoxic, cyclin dependent kinase inhibitor. A phase II trial of flavopiridol followed by ara-C and mitoxantrone with flavopiridol given by 1-h bolus for adults with newly-diagnosed, poor-risk acute myelogenous leukemia yielded 67% complete remission with median disease-free survival of 13.6 months. DESIGN AND METHODS We compared bolus flavopiridol...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2008
Melissa E Smith Velasco Cimica Srinivasa Chinni Kavitha Challagulla Sridhar Mani Ganjam V Kalpana

PURPOSE Rhabdoid tumors are aggressive and incurable pediatric malignancies. INI1/hSNF5, a tumor suppressor biallelically deleted/inactivated in rhabdoid tumors, directly represses cyclin D1. Rhabdoid tumors and cells are exquisitely dependent on cyclin D1 for genesis and survival, suggesting that targeting the cyclin/cyclin-dependent kinase (cdk) axis may be an effective therapeutic strategy f...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2002
Chunrong Yu Geoffrey Krystal Paul Dent Steven Grant

PURPOSE The goal of this study was to characterize interactions between the Bcr/Abl kinase inhibitor STI571 and the cyclin-dependent kinase inhibitor flavopiridol in Bcr/Abl(+) human leukemia cells. EXPERIMENTAL DESIGN K562 leukemia cells were exposed to STI571 +/- flavopiridol for 24 or 48 h, after which mitochondrial damage, caspase activation, expression/activation of signaling and cell cy...

Journal: :Molecular cancer therapeutics 2003
Michelle Alonso Cristina Tamasdan Douglas C Miller Elizabeth W Newcomb

Flavopiridol is a synthetic flavone, which inhibits growth in vitro and in vivo of several solid malignancies such as renal, prostate, and colon cancers. It is a potent cyclin-dependent kinase inhibitor presently in clinical trials. In this study, we examined the effect of flavopiridol on a panel of glioma cell lines having different genetic profiles: five of six have codeletion of p16(INK4a) a...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 1997
M Drees W A Dengler T Roth H Labonte J Mayo L Malspeis M Grever E A Sausville H H Fiebig

We have selected a panel of human tumor xenografts for in vitro and in vivo studies that allows an indication of selectivity of action of novel chemotherapeutic agents. We report here the antitumor activity of the flavone flavopiridol (previously designated L86-8275), which has been selected for further studies based in part on its behavior in the anticancer drug screening system of the United ...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2001
M Motwani C Jung F M Sirotnak Y She M A Shah M Gonen G K Schwartz

CPT-11, a DNA topoisomerase I inhibitor, has demonstrated clinical activity in colorectal cancer. Flavopiridol, a cyclin-dependent kinase inhibitor, is rapidly emerging as a chemotherapy modulator. To enhance the therapeutic index of CPT-11 in colon cancer, we studied the combination of these two drugs in relatively resistant human colon cancer cells, Hct116. Exposure of parental Hct116 cells t...

Journal: :Blood 2000
S Kitada J M Zapata M Andreeff J C Reed

Compounds that inhibit protein kinases are currently undergoing clinical evaluation for the treatment of a variety of malignancies. The kinase inhibitors flavopiridol and 7 hydroxy-staurosporine (UCN-01) were examined for their effects on B-cell chronic lymphocytic leukemia (B-CLL) cells in vitro (n = 49). Flavopiridol and UCN-01 induced concentration-dependent apoptosis of most B-CLL samples t...

2006
Scott H. Kaufmann Keith C. Bible

Flavopiridol (NSC @98%,L86-8275), a potent inhibitor of cyclin dependent kinase 1Jp34@ phosphorylation and kinase activity, is cur rently undergoing Phase I clinical testing as a potential antineoplastic agent. Previous studies have suggested that flavopiridol is cytostatic but not cytotoxic when applied to exponentially growing cells. In the present study, various human tumor cell lines were a...

Journal: :The Journal of pharmacology and experimental therapeutics 2004
Ester Verdaguer Andrés Jiménez Anna M Canudas Elvira G Jordà F Xavier Sureda Mercè Pallàs Antoni Camins

Kainic acid (KA)-induced neuronal damage and the protective effects of flavopiridol were studied in primary cultures of rat cerebellar granule cells (CGNs). When neurons were treated with 500 microM KA, the percentage of cells with condensed nuclei measured by nuclear counting increased by up to 55%. After flavopiridol treatment, an antitumoral drug that is a broad inhibitor of cyclin-dependent...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید